Login to Your Account



'NICE AND EASY' TERMS

TLC and Ablynx agree to jointly develop targeted liposome drug delivery technology

By Dave Silver
Staff Writer

Friday, April 18, 2014

TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription